Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Sell
31
INMB Quote, Financials, Valuation and Earnings
Last price:
$1.71
Seasonality move
:
-28%
Day range:
$1.80 - $1.90
52-week range:
$1.38 - $11.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
889.81x
P/B ratio:
1.97x
Volume:
399.9K
Avg. volume:
467.4K
1-year change:
-57.27%
Market cap:
$50M
Revenue:
$14K
EPS (TTM):
-$2.14
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
INMB
INmune Bio, Inc.
|
-- | -$0.33 | -100% | -39.57% | $5.25 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
INMB
INmune Bio, Inc.
|
$1.88 | $5.25 | $50M | -- | $0.00 | 0% | 889.81x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $6.50 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $685.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
INMB
INmune Bio, Inc.
|
4.08% | -0.166 | 1.96% | 3.77x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
INMB
INmune Bio, Inc.
|
-$28K | -$7.4M | -156.03% | -161.25% | -19810% | -$5.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
INmune Bio, Inc. vs. Competitors
-
Which has Higher Returns INMB or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of -255.85%. INmune Bio, Inc.'s return on equity of -161.25% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital INMBINmune Bio, Inc.-- -$0.24 $26.5M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About INMB or NBY?
INmune Bio, Inc. has a consensus price target of $5.25, signalling upside risk potential of 179.26%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that INmune Bio, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe INmune Bio, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMBINmune Bio, Inc.2 2 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is INMB or NBY More Risky?
INmune Bio, Inc. has a beta of 0.908, which suggesting that the stock is 9.246% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock INMB or NBY?
INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INMB or NBY?
INmune Bio, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. INmune Bio, Inc.'s net income of -$6.5M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 889.81x versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMBINmune Bio, Inc.889.81x -- -- -$6.5M NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns INMB or NNVC?
NanoViricides, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital INMBINmune Bio, Inc.-- -$0.24 $26.5M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About INMB or NNVC?
INmune Bio, Inc. has a consensus price target of $5.25, signalling upside risk potential of 179.26%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 420%. Given that NanoViricides, Inc. has higher upside potential than INmune Bio, Inc., analysts believe NanoViricides, Inc. is more attractive than INmune Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMBINmune Bio, Inc.2 2 0 NNVCNanoViricides, Inc.1 0 0 -
Is INMB or NNVC More Risky?
INmune Bio, Inc. has a beta of 0.908, which suggesting that the stock is 9.246% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock INMB or NNVC?
INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INMB or NNVC?
INmune Bio, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 889.81x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMBINmune Bio, Inc.889.81x -- -- -$6.5M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns INMB or OGEN?
Oragenics, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital INMBINmune Bio, Inc.-- -$0.24 $26.5M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About INMB or OGEN?
INmune Bio, Inc. has a consensus price target of $5.25, signalling upside risk potential of 179.26%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that INmune Bio, Inc. has higher upside potential than Oragenics, Inc., analysts believe INmune Bio, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMBINmune Bio, Inc.2 2 0 OGENOragenics, Inc.1 0 0 -
Is INMB or OGEN More Risky?
INmune Bio, Inc. has a beta of 0.908, which suggesting that the stock is 9.246% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock INMB or OGEN?
INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INMB or OGEN?
INmune Bio, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 889.81x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMBINmune Bio, Inc.889.81x -- -- -$6.5M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns INMB or PTN?
Palatin Technologies has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital INMBINmune Bio, Inc.-- -$0.24 $26.5M PTNPalatin Technologies-- -- -- -
What do Analysts Say About INMB or PTN?
INmune Bio, Inc. has a consensus price target of $5.25, signalling upside risk potential of 179.26%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than INmune Bio, Inc., analysts believe Palatin Technologies is more attractive than INmune Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMBINmune Bio, Inc.2 2 0 PTNPalatin Technologies0 0 0 -
Is INMB or PTN More Risky?
INmune Bio, Inc. has a beta of 0.908, which suggesting that the stock is 9.246% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock INMB or PTN?
INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INMB or PTN?
INmune Bio, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is higher than Palatin Technologies's net income of --. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 889.81x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMBINmune Bio, Inc.889.81x -- -- -$6.5M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns INMB or TOVX?
Theriva Biologics, Inc. has a net margin of -19478% compared to INmune Bio, Inc.'s net margin of --. INmune Bio, Inc.'s return on equity of -161.25% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital INMBINmune Bio, Inc.-- -$0.24 $26.5M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About INMB or TOVX?
INmune Bio, Inc. has a consensus price target of $5.25, signalling upside risk potential of 179.26%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Theriva Biologics, Inc. has higher upside potential than INmune Bio, Inc., analysts believe Theriva Biologics, Inc. is more attractive than INmune Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings INMBINmune Bio, Inc.2 2 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is INMB or TOVX More Risky?
INmune Bio, Inc. has a beta of 0.908, which suggesting that the stock is 9.246% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock INMB or TOVX?
INmune Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. INmune Bio, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios INMB or TOVX?
INmune Bio, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. INmune Bio, Inc.'s net income of -$6.5M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, INmune Bio, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for INmune Bio, Inc. is 889.81x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income INMBINmune Bio, Inc.889.81x -- -- -$6.5M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
Buy
54
UNF alert for Dec 24
UniFirst Corp. [UNF] is up 0.77% over the past day.
